These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 32320170)

  • 41. Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF.
    Barnett AS; Cyr DD; Goodman SG; Levitan BS; Yuan Z; Hankey GJ; Singer DE; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hacke W; Mahaffey KW; Nessel CC; Fox KAA; Patel MR; Piccini JP
    Int J Cardiol; 2018 Apr; 257():78-83. PubMed ID: 29506743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Three-Year Clinical Outcomes Associated With Warfarin vs. Direct Oral Anticoagulant Use Among Japanese Patients With Atrial Fibrillation　- Findings From the SAKURA AF Registry.
    Okumura Y; Yokoyama K; Matsumoto N; Tachibana E; Kuronuma K; Oiwa K; Matsumoto M; Kojima T; Hanada S; Nomoto K; Arima K; Takahashi F; Kotani T; Ikeya Y; Fukushima S; Itou S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
    Circ J; 2018 Sep; 82(10):2500-2509. PubMed ID: 30078823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
    Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
    J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes of non-vitamin K oral anticoagulants for secondary prevention in ischemic stroke with atrial fibrillation.
    Nam KW; Kwon HM; Lee YS; Won SH; Moon HS; Park JH
    Sci Rep; 2024 Apr; 14(1):9838. PubMed ID: 38684879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. To treat or not to treat: a comparative effectiveness analysis of oral anticoagulant outcomes among U.S. nursing home residents with atrial fibrillation.
    Chen Q; Baek J; Goldberg R; Tjia J; Lapane K; Alcusky M
    BMC Geriatr; 2024 Jul; 24(1):619. PubMed ID: 39030486
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
    Wang K; Li H; Kwong WJ; Antman EM; Ruff CT; Giugliano RP; Cohen DJ; Magnuson EA;
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
    Palamaner Subash Shantha G; Bhave PD; Girotra S; Hodgson-Zingman D; Mazur A; Giudici M; Chrischilles E; Vaughan Sarrazin MS
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
    Kido K; Ngorsuraches S
    Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation.
    Kim D; Yang PS; Sung JH; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
    Stroke; 2022 Jun; 53(6):1873-1882. PubMed ID: 35109686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
    Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
    J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Bioprosthetic Heart Valves.
    Duan L; Doctor JN; Adams JL; Romley JA; Nguyen LA; An J; Lee MS
    Am J Cardiol; 2021 May; 146():22-28. PubMed ID: 33529622
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
    Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
    Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
    Fanikos J; Burnett AE; Mahan CE; Dobesh PP
    Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
    Laliberté F; Cloutier M; Nelson WW; Coleman CI; Pilon D; Olson WH; Damaraju CV; Schein JR; Lefebvre P
    Curr Med Res Opin; 2014 Jul; 30(7):1317-25. PubMed ID: 24650301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the Effectiveness and Safety of Direct Oral Anticoagulants in Elderly Patients With Nonvalvular Atrial Fibrillation Who Are Not Candidates for Warfarin in Real-World Setting.
    Lo CT; Niu F; Fredriks DA; Hui RL
    J Cardiovasc Pharmacol; 2022 Jan; 79(1):e138-e143. PubMed ID: 34740212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative Outcomes Between Direct Oral Anticoagulants, Warfarin, and Antiplatelet Monotherapy Among Chinese Patients with Atrial Fibrillation: A Population-Based Cohort Study.
    Li X; Pathadka S; Man KKC; Ng VWS; Siu CW; Wong ICK; Chan EW; Lau WCY
    Drug Saf; 2020 Oct; 43(10):1023-1033. PubMed ID: 32557348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis.
    Tu ZH; Perez AD; Diaz TE; Loop MS; Clarke M
    Tex Heart Inst J; 2024 May; 51(1):. PubMed ID: 38748549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation.
    Wetmore JB; Roetker NS; Yan H; Reyes JL; Herzog CA
    Stroke; 2020 Aug; 51(8):2364-2373. PubMed ID: 32640949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.